Oncology and Hematology - Global Oncology Academy

417-432 of 790

Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
On the Frontlines of Metastatic Breast Cancer
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Ashley Baker, MSN, PMHNP; Giancarlo Moscol, M.D.
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
MinuteCE®
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Hussein Tawbi, MD, PhD; Sapna Patel, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 program credit
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD; Paolo A. Ascierto, MD
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD; Paolo A. Ascierto, MD
1.00 credit 10 episodes
- John M. Kirkwood, MD
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
- Sapna Patel, MD
1.00 credit 10 episodes
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD; Sapna Patel, MD
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
MinuteCE®
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Sapna Patel, MD; John M. Kirkwood, MD
1.00 program credit
- Sapna Patel, MD
- John M. Kirkwood, MD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD; Hussein Tawbi, MD, PhD
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
1.00 program credit
- Paolo A. Ascierto, MD
1.00 program credit
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
On the Frontlines of Metastatic Breast Cancer
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Ryan Quigley
- Ryan Quigley
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Namrata Vijayvergia, MD
- Namrata Vijayvergia, MD
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Junaid Arshad, MD, MS
- Junaid Arshad, MD, MS
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Namrata Vijayvergia, MD
- Namrata Vijayvergia, MD

27/11